Provided by Tiger Trade Technology Pte. Ltd.

Biocryst Pharmaceuticals

8.29
-0.0800-0.96%
Post-market: 8.440.1500+1.81%19:55 EDT
Volume:4.17M
Turnover:34.60M
Market Cap:2.11B
PE:-4.68
High:8.54
Open:8.35
Low:8.22
Close:8.37
52wk High:11.31
52wk Low:6.00
Shares:254.11M
Float Shares:221.00M
Volume Ratio:1.10
T/O Rate:1.88%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.7710
EPS(LYR):1.21
ROE:587.33%
ROA:42.62%
PB:-3.80
PE(LYR):6.85

Loading ...

BioCryst director Amy E. McKee sells 11,180 shares worth $100,284.6

Reuters
·
May 20

BioCryst Chief Legal Officer Alane P. Barnes sells 62,500 shares for $596,250

Reuters
·
May 16

These Analysts Revise Their Forecasts On BioCryst Pharma After Q1 Earnings

Benzinga
·
May 08

BioCryst Pharmaceuticals Is Maintained at Buy by Needham

Dow Jones
·
May 07

BUZZ-U.S. STOCKS ON THE MOVE-Walt Disney, CVS, Uber

Reuters
·
May 06

Stock Track | BioCryst Pharmaceuticals Plunges 6.98% Pre-Market on Surprise Quarterly Loss

Stock Track
·
May 06

Earnings Flash (BCRX) BioCryst Pharmaceuticals Posts Q1 Net Loss $2.98 a Share, vs. FactSet Est of $0.04 EPS

MT Newswires Live
·
May 06

BioCryst Pharma Q1 Adj. EPS $0.14 Beats $0.05 Estimate, Sales $156.413M Beat $151.123M Estimate

Benzinga
·
May 06

BioCryst Q1 operating loss widens to $701.6 million; ORLADEYO revenue rises 11% to $148.3 million

Reuters
·
May 06

BRIEF-BioCryst Pharmaceuticals Q1 EPS USD -2.98

Reuters
·
May 06

BioCryst Pharmaceuticals Inc - Maintains FY2026 Non-Gaap Operating Expense Guidance $450 Mln-$470 Mln

THOMSON REUTERS
·
May 06

BioCryst Pharmaceuticals Q1 Operating Expenses USD 858.011 Million

THOMSON REUTERS
·
May 06

BioCryst Pharmaceuticals Q1 Product Sales USD 3.016 Million

THOMSON REUTERS
·
May 06

Corrected-BioCryst Pharmaceuticals Q1 Product Sales USD 148.3 Million (Corrects Amount)

THOMSON REUTERS
·
May 06

BioCryst Reports First Quarter 2026 Financial Results and Provides Business Update

THOMSON REUTERS
·
May 06

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
May 06

Top News Today: Stocks Rise, Oil Falls, as War Restart Fears Subside

Dow Jones
·
May 06

BioCryst grants 61,750 RSUs to six new hires under inducement plan

Reuters
·
May 05

BioCryst licenses navenibart Europe rights to Neopharmed Gentili affiliate for $70 million upfront

Reuters
·
May 04

BioCryst Pharmaceuticals Inc - to Receive Tiered Royalties of 18%-30% on Net Sales

THOMSON REUTERS
·
May 04